The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinic
American Journal of Medical Genetics Part A · 2024
DOI: 10.1002/ajmg.a.63791 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von Julianne K Postma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, CHEO, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Intellectual Disability, Developmental Disabilities, Genetic Testing. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
First‐tier genetic investigations for patients with neurodevelopmental disorders (NDDs) may include chromosomal microarray, Fragile X testing, and screening for inherited metabolic diseases, but most remain undiagnosed upon completion of testing. Here, we report the diagnostic yields of genetic testing for 537 patients with at least one of autism spectrum disorder, global developmental delay, and/or intellectual disability. Patients were assessed in a single neurodevelopmental genetics clinic, and each underwent a standardized history and physical examination. Each patient was characterized as syndromic or nonsyndromic based on clinical features. Our results demonstrate that multigene sequencing (with an NDD gene panel or exome) had a higher diagnostic yield (8%; 95% confidence interval [CI]: 5%, 13%) than chromosomal microarray and Fragile X testing combined (4%; 95% CI: 3%, 7%). Biochemical screening for inherited metabolic diseases had a diagnostic yield of zero. The diagnostic yield of genetic testing was significantly higher for syndromic patients than for nonsyndromic patients (odds ratio [OR] 3.09; 95% CI: 1.46, 6.83) and higher for female patients than for male (OR 3.21; 95% CI: 1.52, 6.82). These results add to the growing evidence supporting a comprehensive genetic evaluation that includes both copy number analysis and sequencing of known NDD genes for patients with NDDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics, CHEO, Ottawa, Ontario, Canada.
- Clinical Research Unit, CHEO, Ottawa, Ontario, Canada.
- Division of Metabolics and Newborn Screening, Department of Pediatrics, CHEO, Ottawa, Ontario, Canada.
ORCID-Profile: Julianne K Postma, Danielle K Bourque, Andrea C Yu, Melissa T Carter
Zitieren
APA
Postma, J. K., Harrison, M. A., Kutcher, S., Webster, R. J., Cloutier, M., Bourque, D. K., Yu, A. C., & Carter, M. T. (2024). The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinic. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63791
Vancouver
Postma JK, Harrison MA, Kutcher S, Webster RJ, Cloutier M, Bourque DK, et al. The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinic. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63791
BibTeX
@article{Postma2024,
author = {Postma, Julianne K and Harrison, Mary-Ann and Kutcher, Stephen and Webster, Richard J and Cloutier, Mireille and Bourque, Danielle K and Yu, Andrea C and Carter, Melissa T},
title = {The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinic},
journal = {American Journal of Medical Genetics Part A},
year = {2024},
doi = {10.1002/ajmg.a.63791}
}
EUVIMED